biomedicina slovenica


pr=Amir : 89

  1. Adam Roman; Tibau Martorell Ariadna; Molto Valiente Consolación; Šeruga Boštjan; Ocaña Alberto; Amir Eitan; Templeton Arnoud J.
    Clinical benefit of cancer drugs approved in Switzerland 2010‐2019
    2022
  2. Lohmann Ana Elisa; Soldera Sara V.; Pimentel Isabel; Ribnikar Domen; Ennis Marguerite; Amir Eitan; Goodwin Pamela J.
    Association of obesity with breast cancer outcome in relation to cancer subtypes
    2021
  3. Deneau Mark R.; Mack Cara; Perito Emily R.; Ricciuto Amanda; Valentino Pamela L.; Amin Mansi; Amir Achiya; Aumar Madeleine; Auth Marcus; Broderick Annemarie; Homan Matjaž
    The Sclerosing Cholangitis Outcomes in Pediatrics (SCOPE) index
    2021
  4. Ribnikar Domen; Stukalin Igor; Bedard Philippe L.; Hamilton Robert J.; Jewett Michael; Warde Padraig; Chung Peter; Templeton Arnoud J.; Amir Eitan; Lewin Jeremy
    The prognostic value of neutrophil-to-lymphocyte ratio in metastatic testicular cancer
    2020
  5. Gonzales-Conchas Galileo A.; Rodríguez-Romo L.; Hernandez-Barajas D.; Fernández-Rodríguez A.; Hernandez Adrian F.; Templeton Arnoud J.; Ocaña Alberto; Šeruga Boštjan; Tannock Ian F.; Amir Eitan
    Epidermal growth factor receptor overexpression and outcomes in early breast cancer
    2018
  6. Saleh Ramy R.; Meti Nicholas; Ribnikar Domen; Goldvaser Hadar; Ocaña Alberto; Templeton Arnoud J.; Šeruga Boštjan; Amir Eitan
    Associations between safety, tolerability, and toxicity and the reporting of health-related quality of life in phase III randomized trials in common solid tumors
    2020
  7. Šeruga Boštjan; Amir Eitan; Tannock Ian F.
    Hormonal anticancer treatment in the senior cancer patient
    2015
  8. Fernández-Rodríguez A.; Rodríguez-Romo L.; Hernandez-Barajas D.; Gonzalez-Conchas G. A.; Templeton Arnoud J.; Ocaña Alberto; Šeruga Boštjan; Tannock Ian F.; Amir Eitan; Vera-Badillo Francisco Emilio
    Adjuvant radiation therapy after radical nephrectomy in patients with localized renal cell carcinoma
    2019
  9. Deneau Mark R.; Mack Cara; Abdou Reham; Amin Mansi; Amir Achiya; Auth Marcus; Bazerbachi Fateh; Broderick Annemarie; Chan Albert; DiGuglielmo Matthew; Homan Matjaž
    Gamma glutamyltransferase reduction is associated with favorable outcomes in pediatric primary sclerosing cholangitis
    2018
  10. Shepshelovich Daniel; Tibau Martorell Ariadna; Goldvaser Hadar; Molto Valiente Consolación; Ocaña Alberto; Šeruga Boštjan; Amir Eitan
    Postmarketing modifications of drug labels for cancer drugs approved by the US Food and Drug Administration between 2006 and 2016 with and without supporting randomized controlled trials
    2018
  11. Algorashi Ibrahim; Goldvaser Hadar; Ribnikar Domen; Cescon David W.; Amir Eitan
    Evolution in sites of recurrence over time in breast cancer patients treated with adjuvant endocrine therapy
    2018
  12. Goldvaser Hadar; Ribnikar Domen; Majeed Habeeb; Ocaña Alberto; Amir Eitan
    Absolute benefit from adjuvant chemotherapy in contemporary clinical trials
    2018
  13. Goldvaser Hadar; Algorashi Ibrahim; Ribnikar Domen; Šeruga Boštjan; Templeton Arnoud J.; Ocaña Alberto; Amir Eitan
    Efficacy of extended adjuvant therapy with aromatase inhibitors in early breast cancer among common clinicopathologically-defined subgroups
    2017
  14. Goldvaser Hadar; Majeed Habeeb; Ribnikar Domen; Šeruga Boštjan; Ocaña Alberto; Cescon David W.; Amir Eitan
    Influence of control group therapy on the benefit from dose-dense chemotherapy in early breast cancer
    2018
  15. Ribnikar Domen; Goldvaser Hadar; Ocaña Alberto; Templeton Arnoud J.; Šeruga Boštjan; Amir Eitan
    Reporting of randomized trials in common cancers in the lay media
    2018
  16. Barua Reeta; Templeton Arnoud J.; Šeruga Boštjan; Ocaña Alberto; Amir Eitan; Ethier Josee-Lyne
    Hyperglycaemia and survival in solid tumours
    2018
  17. Goldvaser Hadar; Barnes Tristan A.; Šeruga Boštjan; Cescon David W.; Ocaña Alberto; Ribnikar Domen; Amir Eitan
    Toxicity of extended adjuvant therapy with aromatase inhibitors in early breast cancer
    2018
  18. Barnes Tristan A.; Amir Eitan; Templeton Arnoud J.; Gomez-Garcia Susana; Navarro Beatriz; Šeruga Boštjan; Ocaña Alberto
    Efficacy, safety, tolerability and price of newly approved drugs in solid tumors
    2017
  19. Vera-Badillo Francisco Emilio; Napoleone Marc; Krzyzanowska Monika K.; Alibhai Shabbir M.; Chan An-Wen; Ocaña Alberto; Templeton Arnoud J.; Šeruga Boštjan; Amir Eitan; Tannock Ian F.
    Honorary and ghost authorship in reports of randomised clinical trials in oncology
    2016
  20. Adam Roman; Díez-González Laura; Ocaña Alberto; Šeruga Boštjan; Amir Eitan; Templeton Arnoud J.
    Prognostic role of telomere length in malignancies
    2017
  21. Goldvaser Hadar; Ribnikar Domen; Fazelzad Rouhi; Šeruga Boštjan; Templeton Arnoud J.; Ocaña Alberto; Amir Eitan
    Influence of non-measurable disease on progression-free survival in patients with metastatic breast cancer
    2017
  22. Tibau Martorell Ariadna; Díez-González Laura; Navarro Beatriz; Galán-Moya Eva M.; Templeton Arnoud J.; Šeruga Boštjan; Pandiella Atanasio; Amir Eitan; Ocaña Alberto
    Impact of availability of companion diagnostics on the clinical development of anticancer drugs
    2017
  23. Ribnikar Domen; Ratoša Ivica; Perhavec Andraž; Amir Eitan
    General overview and treatment recommendations for young women with breast cancer
    2017
  24. Vera-Badillo Francisco Emilio; Napoleone Marc; Krzyzanowska Monika K.; Alibhai Shabbir M.; Chan An-Wen; Ocaña Alberto; Šeruga Boštjan; Templeton Arnoud J.; Amir Eitan; Tannock Ian
    Bias in reporting of randomised clinical trials in oncology
    2016
  25. Templeton Arnoud J.; Díez-González Laura; Vera-Badillo Francisco Emilio; Tibau Martorell Ariadna; Goldstein Robyn; Šeruga Boštjan; Srikanthan Amirrtha; Pandiella Atanasio; Amir Eitan; Ocaña Alberto
    Interaction between hormonal receptor status, age and survival in patients with BRCA1/2 germline mutations
    2016
  26. Tibau Martorell Ariadna; Ocaña Alberto; Anguera Geòrgia; Šeruga Boštjan; Templeton Arnoud J.; Barnadas Agustí; Amir Eitan
    Oncologic drugs advisory committee recommendations and approval of cancer drugs by the US Food and Drug Administration
    2016
  27. Al Hashem Hashem Yashem; Al-Mubarak Mustafa; Vera-Badillo Francisco Emilio; Templeton Arnoud J.; Ocaña Alberto; Šeruga Boštjan; Amir Eitan
    Impact of geographic region on benefit of approved anticancer drugs evaluated in international phase III clinical trials
    2016
  28. Ocaña Alberto; Díez-González Laura; Garcia-Olmo D. C.; Templeton Arnoud J.; Vera-Badillo Francisco Emilio; Gascón-Escribano María J.; Serrano-Heras G.; Corrales-Sánchez Verónica; Šeruga Boštjan; Andrés-Pretel F.; Pandiella Atanasio; Amir Eitan
    Circulating DNA and survival in solid tumors
    2016
  29. Ocaña Alberto; Pérez-Peña Javier; Díez-González Laura; Corrales-Sánchez Verónica; Templeton Arnoud J.; Šeruga Boštjan; Amir Eitan; Pandiella Atanasio
    Transcriptomic analyses identify association between mitotic kinases, PDZ-binding kinase and BUB1, and clinical outcome in breast cancer
    2016
  30. Ocaña Alberto; Ethier Josee-Lyne; Díez-González Laura; Corrales-Sanchez Verónica; Srikanthan Amirrtha; Gascón-Escribano María J.; Templeton Arnoud J.; Vera-Badillo Francisco Emilio; Šeruga Boštjan; Niraula Saroj; Pandiella Atanasio; Amir Eitan
    Influence of companion diagnostics on efficacy and safety of targeted anti-cancer drugs
    2015
  31. Srikanthan Amirrtha; Vera-Badillo Francisco Emilio; Ethier Josee-Lyne; Goldstein Robyn; Templeton Arnoud J.; Ocaña Alberto; Šeruga Boštjan; Amir Eitan
    Evolution in the eligibility criteria of randomized controlled trials for systemic cancer therapies
    2016
  32. Žist Andrej; Amir Eitan; Ocaña Alberto; Šeruga Boštjan
    Impact of comorbidity on the outcome in men with advanced prostate cancer treated with docetaxel
    2015
  33. Šeruga Boštjan; Ocaña Alberto; Amir Eitan; Tannock Ian
    Failures in phase III
    2015
  34. Ocaña Alberto; Šeruga Boštjan; Amir Eitan
    Pathological complete response in breast cancer
    2015
  35. Tibau Martorell Ariadna; Ocaña Alberto; Šeruga Boštjan; Templeton Arnoud J.; Barnadas Agustí; Amir Eitan
    Association between Oncologic Drugs Advisory Committee (ODAC) members' financial conflicts of interest (FCOIs) and recommendations for drug approval by the U.S. Food and Drug Administration (FDA)
    2015
  36. Amir Eitan; Al-Mubarak Mustafa; Tibau Martorell Ariadna; Templeton Arnoud J.; Ocaña Alberto; Šeruga Boštjan
    Extended adjuvant tamoxifen for early breast cancer
    2013
  37. Vera-Badillo Francisco Emilio; Chang Martin; Kuruzar Gordana; Ocaña Alberto; Templeton Arnoud J.; Šeruga Boštjan; Goldstein Robyn; Bedard Philippe L.; Tannock Ian; Amir Eitan
    Association between androgen receptor expression, Ki-67 and the 21-gene recurrence score in non-metastatic, lymph node-negative, estrogen receptor-positive and HER2-negative breast cancer
    2015
  38. Niraula Saroj; Amir Eitan; Vera-Badillo Francisco Emilio; Šeruga Boštjan; Ocaña Alberto; Tannock Ian
    Risk of incremental toxicities and associated costs of new anticancer drugs
    2014
  39. Al Hashem Hashem Yashem; Al-Mubarak Mustafa; Templeton Arnoud J.; Ocaña Alberto; Šeruga Boštjan; Amir Eitan
    Impact of geographic region on benefit of anticancer agents evaluated in international phase III clinical trials
    2014
  40. Tibau B.; Bedard Philippe L.; Vera-Badillo Francisco Emilio; Templeton Arnoud J.; Ocaña Alberto; Šeruga Boštjan; Barnadas Agustí; Amir Eitan
    Author financial conflicts of interest (FCOIs) in clinical practice guidelines (CPGs) for systemic anti-cancer drugs
    2014
  41. Srikanthan Amirrtha; Ethier Josee-Lyne; Ocaña Alberto; Šeruga Boštjan; Krzyzanowska Monika K.; Amir Eitan
    Cardiovascular toxicity of multi-tyrosine kinase inhibitors in advanced solid tumors
    2015
  42. Templeton Arnoud J.; Diez-Gonzales Laura; Ace Olga; Vera-Badillo Francisco Emilio; Šeruga Boštjan; Jordán Joaquín; Amir Eitan; Pandiella Atanasio; Ocaña Alberto
    Prognostic relevance of receptor tyrosine kinase expression in breast cancer
    2014
  43. Tibau Ariadna; Bedard Philippe L.; Srikanthan Amirrtha; Ethier Josee-Lyne; Vera-Badillo Francisco Emilio; Templeton Arnoud J.; Ocaña Alberto; Šeruga Boštjan; Barnadas Agustí; Amir Eitan
    Author financial conflicts of interest, industry funding, and clinical practice guidelines for anticancer drugs
    2015
  44. Niraula Saroj; Amir Eitan; Vera-Badillo Francisco Emilio; Šeruga Boštjan; Ocaña Alberto; Tannock Ian
    Risk of incremental toxicities and associated costs of new anticancer drugs
    2014
  45. Vera-Badillo Francisco Emilio; Chang Martin; Kuruzar Gordana; Ocaña Alberto; Templeton Arnoud J.; Šeruga Boštjan; Al-Mubarak Mustafa; Goldstein Robyn; Bedard Philippe L.; Tannock Ian; Amir Eitan
    Association between androgen receptor (AR) expression, Ki-67, and the 21-gene recurrence score in early breast cancer
    2014
  46. Vera-Badillo Francisco Emilio; Napoleone Marc; Ocaña Alberto; Templeton Arnoud J.; Šeruga Boštjan; Al-Mubarak Mustafa; Al Hashem Hashem Yashem; Tannock Ian; Amir Eitan
    Effect of multifocality and multicentricity on outcome in early breast cancer
    2014
  47. Niraula Saroj; Amir Eitan; Vera-Badillo Francisco Emilio; Šeruga Boštjan; Ocaña Alberto; Tannock Ian
    Absolute risk and cost of management of toxicities of newly approved anticancer drugs
    2014
  48. Ocaña Alberto; Vera-Badillo Francisco Emilio; Al-Mubarak Mustafa; Templeton Arnoud J.; Corrales-Sanchez Verónica; Diez-Gonzales Laura; Cuenca-Lopez Mária D.; Šeruga Boštjan; Pandiella Atanasio; Amir Eitan
    Activation of the PI3K/mTOR/AKT pathway and survival in solid tumors
    2014
  49. Vera-Badillo Francisco Emilio; Napoleone Marc; Ocaña Alberto; Templeton Arnoud J.; Šeruga Boštjan; Al-Mubarak Mustafa; Al Hashem Hashem Yashem; Tannock Ian; Amir Eitan
    Effect of multifocality and multicentricity on outcome in early stage breast cancer
    2014
  50. Šeruga Boštjan; Zadnik Vesna; Grašič-Kuhar Cvetka; Marinko Tanja; Čufer Tanja; Zakotnik Branko; Zorman Darko; Ocaña Alberto; Amir Eitan
    Association of aromatase inhibitors with coronary heart disease in women with early breast cancer
    2014
  51. Amir Eitan; Carlsson Lindsay; Šeruga Boštjan; Ocaña Alberto; Goodwin P. J.
    A meta-analysis of the association of blood levels of vitamin-D and the risk of breast cancer
    2011
  52. Amir Eitan; Šeruga Boštjan; Ocaña Alberto; Carlsson Lindsay; Bedard Philippe L.
    Pooled analysis of outcomes of T1a/bN0, HER2-amplified breast cancer
    2011
  53. Niraula Saroj; Amir Eitan; Ocaña Alberto; Šeruga Boštjan; Tannock Ian
    The balance between benefits and harms of molecular targeted agents
    2011
  54. Al-Mubarak Mustafa; Tibau Ariadna; Templeton Arnoud J.; Cescon David W.; Ocaña Alberto; Šeruga Boštjan; Amir Eitan
    Extended adjuvant tamoxifen for early breast cancer
    2014
  55. Horgan Anne M.; Šeruga Boštjan; Pond Gregory Russell; Alibhai Shabbir M.; Amir Eitan; De Wit Ronald; Eisenberger Mario A.; Tannock Ian
    Tolerability and efficacy of docetaxel in older men with metastatic castrate-resistant prostate cancer (mCRPC) in the TAX 327 trial
    2014
  56. Vera-Badillo Francisco; Templeton Arnoud J.; Gouveia Paulo de; Diaz-Padilla Ivan; Bedard Philippe L.; Al-Mubarak Mustafa; Šeruga Boštjan; Tannock Ian; Ocaña Alberto; Amir Eitan
    Androgen receptor expression and outcomes in early breast cancer
    2013
  57. Templeton Arnoud J.; McNamara M. G.; Vera-Badillo Francisco; Aneja P.; Ocaña Alberto; Šeruga Boštjan; Leibowitz-Amit R.; Knox Jennifer J; Amir Eitan
    Prognostic role of neutrophil to lymphocyte ratio (nlr) in solid tumors
    2013
  58. Šeruga Boštjan; Zadnik Vesna; Grašič-Kuhar Cvetka; Marinko Tanja; Zorman Darko; Čufer Tanja; Zakotnik Branko; Ocaña Alberto; Amir Eitan
    Aromatase inhibitors and cardiac outcomes in women undergoing cardiac angiography after early breast cancer
    2012
  59. Žist Andrej; Amir Eitan; Ocaña Alberto; Šeruga Boštjan
    Impact of comorbidity on outcome in men with metastatic castrate-resistant prostate cancer (mCRPC)
    2013
  60. Vera-Badillo Francisco; Templeton Arnoud J.; Gouveia Paulo de; Diaz-Padilla Ivan; Bedard Philippe L.; Al-Mubarak Mustafa; Šeruga Boštjan; Tannock Ian; Ocaña Alberto; Amir Eitan
    Androgen receptor expression and outcomes in early breast cancer
    2014
  61. Ocaña Alberto; Vera-Badillo Francisco; Šeruga Boštjan; Pandiella Atanasio; Amir Eitan
    Meta-analysis of HER3 expression and prognosis in solid tumors
    2012
  62. Niraula Saroj; Šeruga Boštjan; Ocaña Alberto; Shao Tiffany; Goldstein Robyn; Tannock Ian; Amir Eitan
    The price we pay for progress
    2012
  63. Ocaña Alberto; Amir Eitan; Vera-Badillo Francisco; Šeruga Boštjan; Tannock Ian
    Phase III trials of targeted anticancer therapies
    2013
  64. Al-Mubarak Mustafa; Sacher Adrian G.; Ocaña Alberto; Vera-Badillo Francisco; Šeruga Boštjan; Amir Eitan
    Fulvestrant for advanced breast cancer
    2013
  65. Šeruga Boštjan; Amir Eitan; Tannock Ian
    Hormonal anticancer treatment in the senior cancer patient
    2010
  66. Ocana Alberto; Vera-Badillo Francisco; Šeruga Boštjan; Templeton Arnoud; Pandiella Atanasio; Amir Etian
    HER3 overexpression and survival in solid tumors: a meta-analysis
    2013
  67. Templeton Arnoud; Ocaña Alberto; Šeruga Boštjan; Vera-Badillo Francisco; Carlsson Lindsay; Bedard Philippe L.; Amir Eitan
    Management of small HER2 overexpressing tumours
    2012
  68. Amir Eitan; Bedard Philippe L.; Ocaña Alberto; Šeruga Boštjan
    Benefits and harms of detecting clinically occult breast cancer
    2012
  69. Ocaña Alberto; Amir Eitan; Šeruga Boštjan; Martin Miguel; Pandiella Atanasio
    The evolving landscape of protein kinases in breast cancer: clinical implications
    2013
  70. Šeruga Boštjan; Pond Gregory Russell; Hertz Paul C; Amir Eitan; Ocaña Alberto; Tannock Ian
    Comparison of absolute benefits of anticancer therapies determined by snapshot and area methods
    2012
  71. Amir Eitan; Šeruga Boštjan; Freedman Orit; Clemons Mark
    Amenorrhoea, menopause, and endocrine therapy for breast cancer
    2009
  72. Amir Eitan; Šeruga Boštjan; Niraula Saroj; Carlsson Lindsay; Ocaña Alberto
    Toxicity of adjuvant endocrine therapy in postmenopausal breast cancer patients: a systematic review and meta-analysis
    2011
  73. Amir Eitan; Šeruga Boštjan; Martinez-Lopez Joaquin; Kwong Ryan; Pandiella Atanasio; Tannock Ian; Ocaña Alberto
    Oncogenic targets, magnitude of benefit, and market pricing of antineoplastic drugs
    2011
  74. Amir Eitan; Šeruga Boštjan; Kwong Ryan; Tannock Ian; Ocaña Alberto
    Poor correlation between progression-free and overall survival in modern clinical trials: are composite endpoints the answer?
    2012
  75. Amir Eitan; Ocaña Alberto; Freedman Orit; Clemons Mark; Šeruga Boštjan
    Dose-dense treatment for triple-negative breast cancer: chemotherapy
    2010
  76. Amir Eitan; Ocaña Alberto; Šeruga Boštjan; Josse Robert; Clemons Mark
    Zoledronic acid for breast cancer therapy-induced bone loss: medical oncology
    2010
  77. Ocaña Alberto; Amir Eitan; Šeruga Boštjan
    Clinical research: show us the data
    2011
  78. Amir Eitan; Šeruga Boštjan; Freedman Orit; Tannock Ian
    Lapatinib plus paclitaxel as first-line therapy for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: inappropriate conclusions from a company-sponsored study?
    2009
  79. Šeruga Boštjan; Amir Eitan; Tannock Ian
    Treatment of lung cancer
    2009
  80. Amir Eitan; Šeruga Boštjan; Serrano Rosario; Ocaña Alberto
    Targeting DNA repair in breast cancer: a clinical and translational update
    2010
  81. Amir Eitan; Freedman Orit C; Šeruga Boštjan; Evans Gareth D
    Assessing women at high risk of breast cancer ea review of risk assessment models
    2010
  82. Šeruga Boštjan; Ocaña Alberto; Niraula Saroj; Amir Eitan
    Absolute benefits of aromatase inhibitors in adjuvant treatment of breast cancer: should we know more?
    2010
  83. Ocaña Alberto; Amir Eitan; Šeruga Boštjan
    Do we have to change the way targeted drugs are developed?
    2010
  84. Amir Eitan; Ocaña Alberto; Šeruga Boštjan; Freedman Orit; Clemons Mark
    Lapatinib and HER2 status: results of a meta-analysis of randomized phase III trials in metastatic breast cancer
    2010
  85. Šeruga Boštjan; Amir Eitan
    Cytochrome P450 2D6 and outcomes of adjuvant tamoxifen therapy: results of a meta-analysis
    2010
  86. Amir O; Kar B; Delgado RM; Younis AG; Gregorič ID; Smart FW; Radovančević B; Frazier OH
    Images in cardiovascular medicine. High left ventricular assist device flows resulting from combined native aortic valve and outflow valve regurgitation
    2005
  87. Amir O; Delgado RM; Kar B; Gregorič I; Radovancevic B; Smart F; Cohn W
    Recovery from multi-organ failure in a patient with a continuous-flow left ventricular assist device
    2005
  88. Amir Offer; Smith Ronald; Nishikawa Akaira; Gregorič Igor D; Smart Frank W
    Left ventricular free wall rupture in acute myocardial infarction: a case report and literature review
    2005
  89. Amir O; Delgado RM; Kar B; Gregorič ID; Radovančević B; Smart F; Cohn W
    Recovery from multi-organ failure in a patient with a continuous-flow left ventricular assist device
    2006


New search      Comments      Top of page Institute for Biostatistics and Medical Informatics